SHANGHAI, July 26,
2024 /PRNewswire/ -- On July
15, Eluminex Biosciences announced that their tri-specific
fusion antibody drug, EB-105, has administered its first dose to a
diabetic macular edema patient in the
United States. This clinical trial, known as LOTUS, is an
open-label, multicenter, single-dose, dose-escalation clinical
trial via intravitreal injection, currently being conducted in four
hospitals across the United
States.
On July 22, 2024, Foreseen
Biotechnology announced the exclusive global licensing of their ADC
targeted drug, FS001, to Ipsen Pharma SAS of France. Ipsen will have exclusive rights to
develop, manufacture, and commercialize FS001 worldwide. The total
licensing fee, including upfront payments, milestone payments, and
sales royalties, amounts to US$1.03
billion.
Eluminex Biosciences's preclinical studies have shown that
EB-105 can effectively inhibit signal transduction pathways such as
VEGF-A/VEGFR-2, Ang-2/Tie-2, and IL-6/IL-6R. In addition to
targeting vascular endothelial growth factor (VEGF) and
angiopoietin-2 (Ang-2), EB-105 also inhibits intracellular
inflammation-related signal transduction pathways, potentially
offering better therapeutic effects for patients with diabetic
retinopathy compared to current therapies.
Foreseen Biotechnology's ADC targeted drug, FS001, is based on a
novel tumor-associated antigen discovered by Foreseen
Biotechnology. It has excellent targeting activity and high
specificity. FS001 uses an innovative, stable, cleavable linker,
coupled with a highly effective topoisomerase I inhibitor,
demonstrating promising preclinical efficacy in various
drug-resistant cancer models.
Sanyou Bio assisted Eluminex Biosciences and Foreseen
Biotechnology in the crucial work of discovering the above
innovative drugs.
Dr. Guojun Lang, CEO of Sanyou
Bio, remarked: "Sanyou Bio is honored to have supported Eluminex
Biosciences and Foreseen Biotechnology in their discovery of
innovative biologic drugs! We wish for the continued success of
these projects in the subsequent R&D, and hope they achieve
clinical success soon to benefit patients worldwide!"
About Eluminex Biosciences
Eluminex was founded in early 2020. The company headquarters,
research and development (R&D) center, and Good Manufacturing
Practices (GMP) manufacturing facilities are located in Suzhou
Industrial Park BioBAY, China, and
the US regional office is located in Mountain View, California. Eluminex is
currently supported by leading venture groups including Lilly Asia
Ventures, Quan Capital, Hillhouse Ventures, and Cenova Capital and
has raised over $100M (USD) through
Series B+ financing.
About Foreseen Biotechnology
We are an emerging biotechnology company that pioneered a high
throughput integrated translational proteomics platform powered by
AI-based data analytical system to accelerate discovery of novel
targets for therapeutics and diagnostics that are clinically
relevant. We are building a pipeline of novel product candidates
for the diagnosis and treatment of cancer, inflammatory/autoimmune
diseases and neurological disorders. Foreseen Biotechnology is
incubated by Nest.Bio Ventures.
About Sanyou Bio
Sanyou Biopharmaceuticals Co., Ltd. is a world-leading high-tech
biotechnology enterprise focusing on R&D and services of
innovative biologic drugs. Sanyou has built the 4C business
patterns that integrate "differentiated CRO, integrated CDO,
innovative CPO and characteristic CRS", to accomplish the mission
"to make the R&D easy for innovative biologics".
Sanyou has established an integrated innovative biologic drug
R&D laboratory with advanced facilities, and has a professional
team with the majority holding a Ph.D. or master degree. Sanyou has
built three industry-leading innovative technology platforms
featured by "super-trillion, integration, and intelligence" , which
are comprised of more than 50 sub-platforms with the core
innovative super-trillion phage display platform, and supported by
platforms of material preparation, biologics discovery, molecule
optimization, in vitro and in vivo efficacy, production cell line
construction, upstream and downstream process development,
preclinical R&D, industrialization development, etc.
Sanyou's business network has expanded to all parts of the
world, including Asia, US and
Europe, and established branches
in Boston, Philadelphia, San
Diego and London. Sanyou
has established friendly business relationships with more than 1000
pharmaceutical companies, drug R&D institutions and diagnostics
companies worldwide. Sanyou received National-level certification
as a high-tech enterprise and a Specialized and Sophisticated
enterprise, and passed the ISO9001 quality assurance certification
and GB/T intellectual property management system certification.
View original
content:https://www.prnewswire.com/news-releases/sanyou-bio-congratulates-eluminex-biosciences-and-foreseen-biotechnology-on-major-breakthroughs-in-innovative-drug-project-302207265.html
SOURCE Sanyou Bio